This legislation, known as the Nitazene Control Act, proposes to permanently classify the entire class of 2-benzylbenzimidazole-opioids , commonly referred to as nitazenes, as Schedule I controlled substances under the Controlled Substances Act. These synthetic opioids are noted for their significant potency, often exceeding that of fentanyl, and their emergence in the illicit drug supply as designer drugs contributing to fatal overdoses. The bill's findings emphasize their high abuse potential and lack of accepted medical use. The act amends Schedule I of the Controlled Substances Act by adding a new subsection that broadly defines 2-benzylbenzimidazole opioids based on their chemical structure and their activity as mu-opioid receptor agonists , explicitly listing several specific compounds. Any nitazene substances previously subject to temporary scheduling will be deemed permanently scheduled upon the act's enactment, streamlining regulatory processes and enforcement. This class-wide permanent scheduling is deemed essential to preemptively counter the rapid proliferation of new nitazene analogs and safeguard public health, while clarifying that existing pathways for legitimate research with Schedule I controlled substances will continue to apply.